Zobrazeno 1 - 3
of 3
pro vyhledávání: '"M P, Fisac"'
Autor:
M. P. Fisac, Josefina Galende, J.A. Gonzalez Hurtado, J.M. Hernández Rivas, M.C. del Cañizo, María Dolores Tabernero, Moro Mj, J. A. Rodriguez
Publikováno v:
British Journal of Haematology. 115:541-544
Recombinant® interferon α (r-IFN-α) has been shown to be an effective drug for chronic myeloid leukaemia (CML). However, higher response rates can be achieved using cytarabine along with r-IFN-α. YNK01 is a derivative of cytosine arabinoside for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7b70a391c24a03b3e384fcc5d01bbdd6
https://doi.org/10.1046/j.1365-2141.2001.03141.x
https://doi.org/10.1046/j.1365-2141.2001.03141.x
Autor:
M C, del Cañizo, M P, Fisac, J, Galende, J A, Hurtado, M J, Moro, J A, Rodriguez, J M, Rivas, M D, Tabernero
Publikováno v:
British journal of haematology. 115(3)
Recombinant(R) interferon alpha (r-IFN-alpha) has been shown to be an effective drug for chronic myeloid leukaemia (CML). However, higher response rates can be achieved using cytarabine along with r-IFN-alpha. YNK01 is a derivative of cytosine arabin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9b8f8206141722f201d4fc924c8f85b6
https://pubmed.ncbi.nlm.nih.gov/11736933
https://pubmed.ncbi.nlm.nih.gov/11736933
Publikováno v:
Sangre. 41(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::bf46e25fdbc5a4c9936947dd9bc8acc8
https://pubmed.ncbi.nlm.nih.gov/9026933
https://pubmed.ncbi.nlm.nih.gov/9026933